Jefferies Financial Group Inc. Purchases Shares of 23,411 Elanco Animal Health Incorporated $ELAN

Jefferies Financial Group Inc. purchased a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 23,411 shares of the company’s stock, valued at approximately $530,000.

A number of other hedge funds have also made changes to their positions in ELAN. UBS Group AG increased its stake in shares of Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after acquiring an additional 5,961,457 shares during the period. Artemis Investment Management LLP acquired a new position in shares of Elanco Animal Health during the fourth quarter valued at approximately $55,693,000. Goldman Sachs Group Inc. increased its stake in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after acquiring an additional 2,445,872 shares during the period. Bowen Hanes & Co. Inc. acquired a new position in shares of Elanco Animal Health during the third quarter valued at approximately $47,626,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Elanco Animal Health by 8.6% during the third quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company’s stock valued at $497,610,000 after acquiring an additional 1,962,276 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insider Buying and Selling at Elanco Animal Health

In other news, insider Rajeev A. Modi bought 4,911 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the acquisition, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. The trade was a 3.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the acquisition, the chief executive officer directly owned 171,971 shares in the company, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by insiders.

Elanco Animal Health Trading Down 0.5%

Shares of NYSE:ELAN opened at $23.86 on Friday. The firm has a fifty day moving average of $22.96 and a two-hundred day moving average of $23.32. The firm has a market capitalization of $11.92 billion, a P/E ratio of -47.72, a price-to-earnings-growth ratio of 2.57 and a beta of 1.69. Elanco Animal Health Incorporated has a 12-month low of $13.09 and a 12-month high of $27.72. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same quarter last year, the business posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities analysts expect that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Leerink Partners lifted their price target on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. KeyCorp lifted their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Citigroup lifted their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Morgan Stanley lifted their price target on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $28.20.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.